Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest & Investment Income (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Interest & Investment Income for 10 consecutive years, with $690000.0 as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 57.33% to $690000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 61.07% year-over-year, with the annual reading at $3.2 million for FY2025, 61.07% down from the prior year.
  • Interest & Investment Income hit $690000.0 in Q4 2025 for Rocket Pharmaceuticals, down from $709000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.0 million in Q1 2024 to a low of $483000.0 in Q2 2025.
  • Historically, Interest & Investment Income has averaged $1.2 million across 5 years, with a median of $880500.0 in 2021.
  • Biggest five-year swings in Interest & Investment Income: soared 258.65% in 2021 and later tumbled 78.95% in 2025.
  • Year by year, Interest & Investment Income stood at $850000.0 in 2021, then soared by 46.47% to $1.2 million in 2022, then plummeted by 34.62% to $814000.0 in 2023, then surged by 98.65% to $1.6 million in 2024, then tumbled by 57.33% to $690000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for RCKT at $690000.0 in Q4 2025, $709000.0 in Q3 2025, and $483000.0 in Q2 2025.